Format

Send to

Choose Destination
Lung Cancer. 2003 Mar;39(3):297-301.

Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking.

Author information

1
Research Division, National Cancer Institute, Rama VI road, Ratchatewi, 10400, Bangkok, Thailand. sulee@health.moph.go.th

Abstract

Abnormalities of p53 gene can lead to the production of p53 antibodies (p53-Abs) in the serum of cancer patients. This study was designed to investigate the prevalence of p53-Abs in 133 lung cancer patients and the distribution of these antibodies to clinicopathologic features and smoking status. Twenty five (18.8%) lung cancer patients were found to have p53-Abs. The presence of p53-Abs did not correlate with sex or age but showed frequent association with tumors of squamous cell carcinoma (31%) in comparison with adenocarcinoma (13.6%) (P=0.052). There was a statistically significant difference in the incidence of p53-Abs between early disease group (stage I-II) and the advanced group (stage III-IV) (P=0.036), however, there was no relationship between the presence of p53-Abs and overall survival. Interestingly, the frequent of p53-Abs was higher in smokers (27.1%) than in non-smokers (13.6%), though the difference was of borderline of statistical significance (P=0.061). These findings suggested that p53-Abs could be a potential biomarker for the study of individual with lung cancer.

PMID:
12609568
DOI:
10.1016/s0169-5002(02)00509-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center